泰国重组无细胞百日咳疫苗上市后安全性主动监测
泰国对2016年获批的重组无细胞百日咳疫苗(aPgen及TdaPgen)开展上市后主动药物警戒监测,2017年5月至2020年2月共收集11,429名接种青少年和成人(含1,778名孕妇)的安全性数据。AEFI发生率为11.5/1000(95%CI 9.7-13.6),多为轻微局部疼痛和肌痛,无疫苗相关严重不良事件。
要点
- 11,429名接种者中AEFI发生率为11.5/1000,多为轻微局部反应。
- 孕妇接种后AEFI发生率为1.1/1000,未报告疫苗相关严重不良事件。
- 833名孕妇中91.4%妊娠无并发症,855名婴儿中98.7%健康出生。
核心结论
- 主动药物警戒确认重组百日咳疫苗aPgen和TdaPgen在青少年、成人及孕中晚期接种孕妇中安全性良好。
研究设计与样本
- 上市后主动药物警戒监测,2017年5月至2020年2月(TdaPgen)和2018年6月至2020年2月(aPgen)纳入11,429名≥11岁接种者,含1,778名孕妇。
主要发现
- 接种者AEFI发生率为11.5/1000(95%CI 9.7-13.6),主要为注射部位疼痛和肌痛,症状轻微,多在数天内缓解且无并发症。
- 孕期接种女性AEFI发生率为1.1/1000(95%CI 0.3-4.1)。
- 833名接种孕妇中91.4%(95%CI 89.3-93.3)妊娠无并发症,其所生855名婴儿中98.7%(95%CI 97.7-99.4)健康出生。
- 监测期间未报告疫苗相关严重不良事件。
临床怎么用
- 可为≥11岁青少年和成人,包括孕中晚期孕妇,接种重组百日咳疫苗的安全性提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A new generation of recombinant acellular pertussis vaccine containing genetically inactivated pertussis toxin (PTgen) was licensed as a monovalent pertussis vaccine (aPgen; Pertagen®) and in combination with tetanus and reduced-dose diphtheria (TdaPgen; Boostagen®) for active immunization in individuals aged 11 years and older in Thailand in 2016. We here report post-marketing safety data on the use of the vaccines in individuals in the community obtained through active pharmacovigilance surveillance including pregnant women participating in a prospective observational study. Between May 2017 and February 2020 for TdaPgen and between June 2018 and February 2020 for aPgen, participating health care providers vaccinated and collected safety data for 11,429 exposed adolescents and adults. This included 1778 pregnant women. The incidence rate of adverse events following immunization (AEFIs) was 11.5 per 1000 of vaccinated individuals (95% confidence interval (95% CI) 9.7-13.6). AEFIs mostly concerned local pain at the injection site and muscle pain, and symptoms were mild and mostly resolved within a few days with no complications. The incidence rate of AEFIs in women vaccinated during pregnancy was 1.1 per 1000 (95% CI 0.3-4.1). Of 833 pregnant women vaccinated with recombinant aPgen or TdaPgen, 91.4% (95% CI 89.3-93.3) had uncomplicated pregnancies and 98.7% (95% CI 97.7-99.4) of the 855 babies delivered by these women were born healthy, which exceeds rates generally reported in Thailand. There were no vaccine-related serious adverse events reported during the surveillance period. In conclusion, active pharmacovigilance confirms that the recombinant pertussis vaccines aPgen (Pertagen) and TdaPgen (Boostagen) are safe in adolescents and adults, including pregnant women vaccinated in the second or third trimester of pregnancy.
引用
- Fortuna L, Chaithongwongwatthana S, Soonthornworasiri N, et al. Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand. Vaccine. 2020. PMID: 33176935. doi:10.1016/j.vaccine.2020.10.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。